Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, headquartered in the United States, is a pioneering leader in the biotechnology industry, specialising in immune-driven medicine. Founded in 2009, the company has made significant strides in harnessing the power of the adaptive immune system to develop innovative diagnostic and therapeutic solutions. With a focus on areas such as oncology and infectious diseases, Adaptive Biotechnologies offers unique products like the clonoSEQ® assay, which provides precise insights into the immune repertoire. This technology stands out for its ability to detect and quantify specific immune cells, enabling personalised treatment strategies. Recognised for its contributions to precision medicine, Adaptive Biotechnologies has established a strong market position, collaborating with major pharmaceutical companies and research institutions to advance the field of immunology.
DitchCarbon Score
How does Adaptive Biotechnologies's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adaptive Biotechnologies's score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adaptive Biotechnologies's reported carbon emissions
Adaptive Biotechnologies, headquartered in the United States, currently does not report any specific carbon emissions data, as indicated by the absence of figures in kg CO2e. However, the company is committed to climate action, having established near-term reduction targets as part of its sustainability initiatives. As of June 2025, Adaptive Biotechnologies has committed to near-term targets, although specific numerical goals have not been disclosed. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector, which is increasingly focusing on reducing its environmental impact. Adaptive Biotechnologies has not yet set long-term targets or a net-zero commitment, but its commitment to near-term targets reflects a proactive approach to addressing climate change. The company’s initiatives are aligned with industry standards and demonstrate a recognition of the importance of sustainability in the biotechnology field. Overall, while specific emissions data is not available, Adaptive Biotechnologies is taking steps towards climate responsibility through its commitment to reduction targets.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Adaptive Biotechnologies is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
